CD274 and colorectal carcinoma: In the adjuvant setting, one ongoing trial (Alliance A021502, NCT02912559), is evaluating the role of PD-L1 blockade in patients with stage 3 MSI-H CRC, using mFOLFOX6 with or without atezolizumab.